Omnihealth Practice

RESPIROLOGY

Beyond breathlessness: The evolving landscape of ILD management

20 May 2025

HFNC oxygen supplementation and SF ratio prognostication in the COVID-19 pandemic

14 Mar 2024

Fixed-duration immunotherapy demonstrates comparable survival benefits in advanced NSCLC

11 Jul 2023

Dupilumab demonstrates long-term safety and efficacy among children with type 2 asthma: The EXCURSION study

15 May 2023

Targeting TSLP for severe asthma - Tezepelumab updates from the 2023 American Academy of Allergy Asthma & Immunology Annual Meeting

06 Apr 2023

Real-world effectiveness of benralizumab insevere EOS asthma: The interim integratedanalysis from the XALOC-2 study

29 Mar 2023

Remission is within reach - Target the underlying drivers of inflammation with benralizumab

19 Sep 2022

The potential new first-line mNSCLC treatment regardless of PD-L1: Durvalumab + tremelimumab + chemotherapy improved survival

03 May 2022

Using adjuvant osimertinib to treat resected EGFR mutationpositive NSCLC in early stages: A local case sharing

27 Feb 2022

Ambulatory management of spontaneous pneumothorax: recent evidence and a case study

27 Feb 2022

Beyond breathlessness: The evolving landscape of ILD management

Interstitial lung disease (ILD) presents as a diverse group of lung disorders, where inflammation and fibrosis drive a highly variable disease course.1,2 While some patients experience mild symptoms, others progress to debilitating respiratory failure, highlighting the unpredictable nature of ILD.1,

20 May 2025

Dr. Syazatul Syakirin Sirol Aflah

Consultant Respiratory Physician,
Institut Perubatan Respiratori (IPR),
Kuala Lumpur, Malaysia

HFNC oxygen supplementation and SF ratio prognostication in the COVID-19 pandemic

To manage the large influx of patients during the Omicron surge of the coronavirus disease 2019 (COVID-19), the Hospital Authority (HA) expanded the use of high-flow nasal cannula (HFNC) oxygen therapy devices in the general wards of hospitals in Hong Kong.1 In an interview with Omnihealth Practice,

14 Mar 2024

Dr. Chan, Yu-Hong John

Specialist in Respiratory Medicine

Dr. Tong, Chak-Kwan

Specialit in Critical Care Medicine,
Adult Intensive Care Unity,
Tuen Mun Hospital

ERS 2023

September 9 - 13, 2023 | Milan, Italy

Adopting durvalumab consolidation therapy: A breakthrough for non-small cell lung cancer treatment

ONCOLOGY RESPIROLOGY

10 Dec 2021

Dr. Lee, Ho-Fun Victor

Clinical Associate Professor,
Department of Clinical Oncology,
The University of Hong Kong

Dr. Chan, Siu-Hong Oscar

Specialist in Clinical Oncology,
Hong Kong Integrated Oncology Centre

Dr. Nyaw, Shi-Feng Jonathan

Specialist in Clinical Oncology,
Department of Clinical Oncology,
Tuen Mun Hospital

Using adjuvant osimertinib to treat resected EGFR mutationpositive NSCLC in early stages: A local case sharing

Accounted for 15.4% of new cancer cases in 2018, lung cancer is one of the most common cancers in Hong Kong, with around 30% of patients having resectable non-small cell lung cancer (NSCLC).^1,2 While adjuvant chemotherapy is the current postoperative standard of care, this treatment could only reduce the risk of disease recurrence or death by 16%.²Recently, the ADAURA trial demonstrated that osimertinib, when utilized as an adjuvant therapy with or without chemotherapy, could prolong the disease-free survival (DFS) of patients with resected stage IB to IIIA epidermal growth factor receptor (EGFR) mutation positive NSCLC.² In a recent interview with Omnihealth Practice, Dr. Tsang, Wai-Kong Maverick, shared a local patient case with resected stage IB EGFR mutation-positive lung adenocarcinoma who was well-tolerated to the postoperative adjuvant osimertinib without chemotherapy for 10 months.

27 Feb 2022

Dr. Tsang, Wai-Kong Maverick

Specialist in Clinical Oncology

Sketching the roadmap for Asian lung cancer management: Expert consensus on lung cancer screening practices in Asian populations

Lung cancer (LC) is regarded as the most lethal form of cancer in Asia.¹ In 2020, the World Health Organization (WHO) ’s Global Cancer Observatory (GLOBOCAN) estimated that 60% of global LC cases and 62% of global LC-related mortality were from Asian countries.¹

16 Nov 2023

Dr. Lam, Chi-Leung David

Chief of Respiratory Medicine Division Clinical Associate Professor, Department of Medicine,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

J Thorac Oncol. 2023.

Lam D. C. L., Liam C. K., Andarini S., Park S., Tan D. S. W., Singh N., Jang S. H., Vardhanabhuti V., Ramos A. B., Nakayama T., Nhung N. V., Ashizawa K., Chang Y. C., Tscheikuna J., Van C. C., Chan W. Y., Lai Y. H., Yang P. C. Lung Cancer Screening in Asia: An Expert Consensus Report. J Thorac Oncol. 2023;18(10):1303-1322.

Short-course inhaled amikacin therapy reduces the risk of VAP in patients who received recent invasive mechanical ventilation

Ventilator-associated pneumonia (VAP) is a common nosocomial infection associated with significant morbidity, especially for patients in intensive care units (ICU).1 Previous clinical trials had evaluated the use of inhaled preventive antibiotics such as colistin, ceftazidime, and gentamicin in pati

03 Jan 2024

Reducing unnecessary antibiotics use in children with acute sinusitis through bacterial testing

A recent randomized clinical trial suggests that undergoing testing for specific nasopharyngeal bacteria in children with acute sinusitis could identify those who will benefit most from antibiotic treatment.1 Consequently, this could in turn substantially reduce antibiotic use among pediatric patien

11 Sep 2023

RESPIROLOGY

Brain Gliosis: A Potential Origin of Persistent Post-COVID-19 Depressive and Cognitive Symptoms

17 Nov 2023

Beyond breathlessness: The evolving landscape of ILD management

20 May 2025

Dr. Syazatul Syakirin Sirol Aflah

Consultant Respiratory Physician,
Institut Perubatan Respiratori (IPR),
Kuala Lumpur, Malaysia